SORRENTO THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.015 USD | 0.00% |
|
-45.45% | -87.85% |
| Mar. 15 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
| Mar. 12 | News Highlights : Top Company News of the Day - Tuesday at 5 AM ET | DJ |
Financials (USD)
| Sales 2021 | 52.9M | Sales 2022 | 62.84M | Capitalization | 411M |
|---|---|---|---|---|---|
| Net income 2021 | -428M | Net income 2022 | -573M | EV / Sales 2021 | 29.1 x |
| Net Debt 2021 | 111M | Net Debt 2022 | 84.53M | EV / Sales 2022 | 7.89 x |
| P/E ratio 2021 |
-3.2
x | P/E ratio 2022 |
-0.65
x | Employees | 949 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.77% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -25.00% | ||
| 1 week | -54.55% | ||
| Current month | +87.50% | ||
| 1 month | +87.50% | ||
| 3 months | -40.00% | ||
| 6 months | -82.76% | ||
| Current year | -87.85% |
1 week
0.00
0.05
1 month
0.000.08
Current year
0.000.14
1 year
0.000.42
3 years
0.0011.07
5 years
0.0019.39
10 years
0.0026.80
| Managers | Title | Age | Since |
|---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 59 | 88-12-31 |
Shawn Sahebi
COO | Chief Operating Officer | - | - |
Mike A. Royal
CTO | Chief Tech/Sci/R&D Officer | 70 | 14-03-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kim D. Janda
BRD | Director/Board Member | 67 | 12-03-31 |
David Lemus
BRD | Director/Board Member | 61 | 17-09-30 |
Jaisim Shah
BRD | Director/Board Member | 63 | 13-09-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 0.015 | 0.00% | 41 598 |
| 24-04-22 | 0.015 | -25.00% | 136,932 |
| 24-04-19 | 0.02 | -16.67% | 198,999 |
| 24-04-18 | 0.024 | -14.29% | 56,700 |
| 24-04-17 | 0.028 | +1.82% | 42,473 |
Delayed Quote OTC Markets, April 22, 2024 at 03:59 pm EDT
More quotes
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Companyâs segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Companyâs immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.
| 1st Jan change | Capi. | |
|---|---|---|
| -87.85% | 8.16M | |
| +2.49% | 96.73B | |
| -1.86% | 21.31B | |
| -16.61% | 21.21B | |
| -5.80% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B | |
| -21.79% | 8.56B |
- Stock Market
- Equities
- SRNE Stock
